HERG K+ channels: friend and foe.

The K+ channel encoded by the human ether-à-go-go related gene (HERG) is one of many ion channels that are crucial for normal action potential repolarization in cardiac myocytes. HERG encodes the pore-forming subunit of the rapid component of the delayed rectifier K+ channel, I(K(Vr)). HERG K+ channels are of considerable pharmaceutical interest as possible therapeutic targets for anti-arrhythmic agents and as the molecular target responsible for the cardiac toxicity of a wide range of pharmaceutical agents. Recent studies of the molecular basis of the promiscuity of HERG K+ channel drug binding has not only started to shed light on this tricky pharmaceutical problem but has also provided further insights into the structure and function of HERG K+ channels.

[1]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[3]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[4]  B. Singh,et al.  A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 , 1970, British journal of pharmacology.

[5]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[7]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L Goldman,et al.  The autopsy in clinical medicine. , 1989, Mayo Clinic proceedings.

[9]  A. Brown,et al.  Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.

[10]  E. Marbán.  Heart Failure: , 1999, Journal of cardiovascular electrophysiology.

[11]  Harry J. Witchel,et al.  Time course and voltage dependence of expressed HERG current compared with native ”rapid” delayed rectifier K current during the cardiac ventricular action potential , 1998, Pflügers Archiv.

[12]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.

[13]  C. Antzelevitch,et al.  Sodium Pentobarbital Reduces Transmural Dispersion of Repolarization and Prevents Torsades de Pointes in Models of Acquired and Congenital Long QT Syndrome , 1999, Journal of cardiovascular electrophysiology.

[14]  M Restivo,et al.  Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. , 1997, Circulation.

[15]  A. Brown,et al.  Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.

[16]  D. Roden.  Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. , 1996, Circulation.

[17]  Christopher Miller.  The inconstancy of the human heart , 1996, Nature.

[18]  Dimarco Jp,et al.  Cardiovascular drugs. Dofetilide. , 2000 .

[19]  J. K. Gibson,et al.  Comparative Assessment of Ibutilide, D‐Sotalol, Clofilium, E‐4031, and UK‐68, 798 in a Rabbit Model of Proarrhythmia , 1993, Journal of cardiovascular pharmacology.

[20]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[21]  C. Antzelevitch,et al.  Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell. , 1995, Circulation research.

[22]  J. Kaprio,et al.  Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects , 2000, Human mutation.

[23]  A. Brown,et al.  Blockade of HERG and Kv1.5 by ketoconazole. , 1998, The Journal of pharmacology and experimental therapeutics.

[24]  M. Sanguinetti,et al.  Mutations of the S4‐S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes , 1999, The Journal of physiology.

[25]  J. Balser,et al.  Probing the Interaction Between Inactivation Gating and d-Sotalol Block of HERG , 2000, Circulation research.

[26]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[27]  M. Sanguinetti,et al.  Molecular Genetic Insights into Cardiovascular Disease , 1996, Science.

[28]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[29]  J. Benhorin,et al.  Images in clinical medicine. Congenital long-QT syndrome. , 1997, The New England journal of medicine.

[30]  S. Hohnloser,et al.  Drug therapy : Sotalol , 1994 .

[31]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[32]  Glenn I. Fishman,et al.  Cyclic AMP regulates the HERG K+ channel by dual pathways , 2000, Current Biology.

[33]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[34]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[35]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[36]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[37]  G. Robertson,et al.  Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E‐4031 from HERG to M‐eag channels , 1998, The Journal of physiology.

[38]  M Restivo,et al.  The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. , 1996, Circulation research.

[39]  D. Roden,et al.  Clinical features and basic mechanisms of quinidine-induced arrhythmias. , 1986, Journal of the American College of Cardiology.

[40]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[41]  A J Moss,et al.  Spectrum of Mutations in Long-QT Syndrome Genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 , 2000, Circulation.

[42]  J. Camm,et al.  Risk of torsades de pointes with non-cardiac drugs , 2000, BMJ : British Medical Journal.

[43]  D M Roden,et al.  The long QT syndromes: genetic basis and clinical implications. , 2000, Journal of the American College of Cardiology.

[44]  R. Hauer,et al.  Genetic and molecular basis of cardiac arrhythmias : Impact on clinical management , 1999 .

[45]  E. Carmeliet.  Cardiac ionic currents and acute ischemia: from channels to arrhythmias. , 1999, Physiological reviews.

[46]  Yi Liu,et al.  Blocker protection in the pore of a voltage-gated K+ channel and its structural implications , 2000, Nature.

[47]  I. Shrivastava,et al.  Structure and dynamics of K channel pore-lining helices: a comparative simulation study. , 2000, Biophysical journal.

[48]  J. Tamargo.  Drug-induced torsade de pointes: from molecular biology to bedside. , 2000, Japanese journal of pharmacology.

[49]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[50]  Arthur J. Moss,et al.  The QT Interval and Torsade de Pointes , 1999, Drug safety.

[51]  S. Priori,et al.  Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias , 2000, Journal of cardiovascular electrophysiology.

[52]  M. Sanguinetti,et al.  Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. , 1996, Circulation research.